Hansa Biopharma (HNSA.ST)

Executive Summary

Hansa Biopharma is a Swedish biopharmaceutical company specializing in innovative immunomodulating therapies for rare IgG-driven autoimmune conditions. Its lead product, Idefirix (imlifidase), is approved in Europe for desensitization of highly sensitized kidney transplant patients, enabling transplantation across HLA-incompatible barriers. The company is advancing a pipeline targeting autoimmune diseases such as anti-GBM disease and Guillain-Barré syndrome, with ongoing clinical trials. Hansa's unique IgG-cleaving enzyme technology has the potential to address significant unmet needs in transplantation and autoimmunity, but commercialization in Europe is still ramping up, and US regulatory approval remains a key near-term milestone. With a strong scientific foundation and a focus on rare diseases, Hansa is positioned for growth, though competition and regulatory risks persist.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on imlifidase for kidney transplant desensitization (US BLA approval)65% success
• Q1 2027Phase 2 topline results for imlifidase in anti-GBM disease55% success
• TBDPotential partnership or licensing deal for imlifidase in autoimmune indications60% success